NovaBay Pharmaceuticals Inc banner

Earnings Calls

Last Earnings Call

Fiscal Period
Q1 2024
Call Date
May 9, 2024
AI Summary
Q1 2024

Record sales: NovaBay said Avenova ordered sales hit all-time highs on Amazon in March and April, with April sales more than 20% higher than a year ago.

Q1 growth: First-quarter total sales rose 12% to $2.6 million, driven mainly by stronger online Avenova sales.

Efficiency gains: Sales and marketing expense fell 50% to $1.1 million even as online sales improved, reflecting more efficient digital advertising.

Strategic shift: Management emphasized the company’s move to focus on eyecare and the dry eye market, which it described as large and growing.

New partnership: NovaBay completed training with Eyenovia and expects the co-marketing launch of clobetasol in the third quarter.

Profit impact: Net loss widened to $3.6 million, largely reflecting a noncash divestiture loss and other financing-related items.

Key Financials
Total sales net
$2.6 million
Eyecare business sales
$2.4 million
Online sales
more than $2 million
Sales and marketing expense
$1.1 million
Gross margin
68%
G&A expense
$2.3 million
R&D expense
$19,000
Net loss attributable to common stockholders
$3.6 million
Net loss per share
$0.15
Cash and cash equivalents
$1.8 million
Noncash loss from divestiture
$865,000
Gain on change in fair value of warrant liabilities
$194,000
Gain on change in fair value of embedded derivative liability
$65,000
Accretion of discount on convertible notes
$433,000
Other expense, net
$480,000
April 2024 ordered product sales
more than 20% higher than April 2023
March and April ordered sales
all-time record high
Earnings Call Recording

Other Earnings Calls